Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. - Wikidata - awgldk - TriplyDB

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

http://www.wikidata.org/entity/Q44807764

about

High levels of anti-inflammatory and pro-resolving lipid mediators lipoxins and resolvins and declining docosahexaenoic acid levels in human milk during the first month of lactation High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: implications for airway inflammation in cystic fibrosis Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease Resolvins and omega three polyunsaturated fatty acids: Clinical implications in inflammatory diseases and cancer Key mechanisms governing resolution of lung inflammation Resolution of inflammation in asthma Lipidomic profiling of bioactive lipids by mass spectrometry during microbial infections Modulation of the Activities of Neuronal Ion Channels by Fatty Acid-Derived Pro-Resolvents DHA- and EPA-derived resolvins, protectins, and maresins in airway inflammation Specialized pro-resolving mediators: endogenous regulators of infection and inflammation Redox-dependent anti-inflammatory signaling actions of unsaturated fatty acids Altered cholesterol homeostasis in cultured and in vivo models of cystic fibrosis Resolution of acute inflammation in the lung Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators ATF3 is a novel regulator of mouse neutrophil migration Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus.Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis.Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators.Lipoxin A4 and platelet activating factor are involved in E. coli or LPS-induced lung inflammation in CFTR-deficient mice.Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators.Genetic variation and clinical heterogeneity in cystic fibrosis Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?Translation control: a multifaceted regulator of inflammatory response Inflammation and its resolution as determinants of acute coronary syndromes.Effect of allergy and inflammation on eicosanoid gene expression in CFTR deficiency.Resolution of Cochlear Inflammation: Novel Target for Preventing or Ameliorating Drug-, Noise- and Age-related Hearing Loss.Impaired clearance of apoptotic cells in chronic inflammatory diseases: therapeutic implications Lipoxin A4 stimulates calcium-activated chloride currents and increases airway surface liquid height in normal and cystic fibrosis airway epithelia.SOCS2-induced proteasome-dependent TRAF6 degradation: a common anti-inflammatory pathway for control of innate immune responses Neutrophil unsaturated fatty acid release by GM-CSF is impaired in cystic fibrosis Abnormal unsaturated fatty acid metabolism in cystic fibrosis: biochemical mechanisms and clinical implications.Resolvin D1 limits 5-lipoxygenase nuclear localization and leukotriene B4 synthesis by inhibiting a calcium-activated kinase pathway.Endogenous lipid mediators in the resolution of airway inflammation Protectin D1 is generated in asthma and dampens airway inflammation and hyperresponsiveness Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling Physiological levels of lipoxin A4 inhibit ENaC and restore airway surface liquid height in cystic fibrosis bronchial epithelium Targeting pro-resolution pathways to combat chronic inflammation in COPD

P2860

Q21245689-25B31C56-C92B-4C37-A097-921EFF936C3D Q24545304-761EC37D-66E7-4AFB-A149-64061665ACBA Q24605366-41215B83-8C1D-4413-BF4C-DFE79C259A72 Q24621702-D71D0B3E-F2C9-49BD-8930-033D6CCD0B32 Q26741524-EE8DE42C-76B6-4229-A592-395124883BBC Q26749606-12B0E2D1-ACA7-4575-B72E-3B7002E78A06 Q26823724-3E638555-510D-40E3-8D51-FAB507592DAC Q26825122-63212C18-315A-4968-8F05-759D273C1636 Q28069355-0D4685C9-6E74-425C-A5C0-463DD506B74E Q28269550-D6974FAB-2AAE-42C1-9798-CF02A74B7991 Q28271331-BA3E33CE-849B-4F18-83F0-253E0EE273B4 Q28386488-DC15D779-1256-48C0-A0A8-2D6F9194CE06 Q28509055-C1292D35-F1E9-4623-9DD2-FD6152EBEA64 Q28652204-E9CE8056-E3D6-4BDD-B950-8C4E4BF64F11 Q28716294-EFF0D8B2-D31B-4259-BD85-ED37E274BDD2 Q29615694-2D1E160D-B4E3-43A1-8E26-14418412CB6E Q30574792-B442A5C7-E469-40E8-9DB7-96DE28442CA2 Q31134484-9C5544B7-AB3F-4385-B811-4BC818E61720 Q33298018-289BAAB5-A08B-46CA-8CA3-A8CFB6CBB579 Q33384350-3E5D231D-7063-45F7-976A-70EB386567F5 Q33414226-AF3E5AA7-5A45-4C43-B80A-C68681A10503 Q33437576-BE43046B-9BB0-4457-BBD1-CB5BA88B645A Q33645546-73366B46-F398-49A1-959D-D319C1A447CC Q33683210-4EBB3E02-3AB0-4A73-8076-18F7C86B4A14 Q33814325-1469C9AC-E2C1-4C18-AC06-DA3884B85C40 Q33834800-CBC0F630-EF74-4E92-A057-1AE2694D3755 Q33863162-288983A0-732F-4E2E-925F-0D167F66E7CB Q33882297-1A489CCD-78C5-446F-B046-73FA7A12C8F8 Q33984427-87019D35-72FB-464F-83B3-5DA49CD5890E Q34291214-559D01FD-4937-4C7E-9285-A3F163A74EF9 Q34302552-C2340B82-2A62-43C5-AC08-79E7E22A308B Q34335733-5D667C7E-F150-428E-9606-6B40C107E78D Q34358489-1E884118-FF66-4990-A08E-DACC1CA5C6E7 Q34407602-4752A80E-4A78-4D6D-970A-72F5E937D4BB Q34423359-EA56D07D-881C-4BDF-979A-6E8DF3569F8E Q34423365-02B11BDE-AE72-4BE0-92F3-31C6203CCE46 Q34522097-436240FF-C00C-4946-B169-02367AE5736C Q34523903-987DBA1F-3BDC-476A-B292-DC3FA5853DBB Q34582407-0734E77B-6858-40D7-81A7-F148B835EBD1 Q34628609-45894386-B9BA-4606-A566-2E428ADF7DFD

P2860

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

http://www.wikidata.org/entity/Q44807764

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

@en

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

@nl

type

label

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

@en

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

@nl

prefLabel

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

@en

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

@nl

P1433

Q44807764-10D00AA0-260A-4B5C-84C4-DF401FA7A241

P1476

Q44807764-5EBE57BC-714C-4B54-8626-B17D523D4A26

P2093

Q44807764-103311D8-1DDA-408C-8DFE-A340333AC670

Q44807764-1BD5E144-F88F-4A4B-9B52-6ABCFAE4D4C2

Q44807764-2DC8D9A4-CFF6-4962-80BC-2F397499E878

Q44807764-4DE30008-BE06-4A27-A9C1-CD627F10DE4E

Q44807764-77DA3EA7-65BF-4CC3-A7DD-4202DD810E04

Q44807764-7F7B4563-22D3-4EED-A648-E13BDE3AFD9B

Q44807764-B9F1B279-698D-4C9A-A489-661476259553

Q44807764-CB01BE88-8DCB-4A0F-BF00-BB4F3913EF0B

Q44807764-CDC71167-652E-4B9D-9D90-AF2B7F02FE75

Q44807764-D3331993-7845-407E-9BC4-F27554497B85

P304

Q44807764-125E8655-75EB-4585-9778-6FA4F87ABCF0

P31

Q44807764-519FBEB7-A246-4171-AAB7-2BEFAFFFF4C4

P356

Q44807764-9E3B6B4E-893D-4472-87BA-ADD66D3B8C41

P407

Q44807764-3BD7C432-A2DF-4137-893C-CB830B116704

P433

Q44807764-A3791F72-2FF3-4783-AFFB-72E61428827F

P478

Q44807764-03DAFAFD-A243-41CB-A61C-FEF8CD86D2AD

P50

Q44807764-6A7B6239-E213-430B-8545-0B6A6D14A91B

Q44807764-BB675D88-4483-444D-A5B0-11BF6264BAE5

Q44807764-BCD35BA9-E06B-4C10-963B-D0B2692FC6DB

Q44807764-DE8E2EB8-17E1-4FAE-9F6B-D29E38A2C5BA

P577

Q44807764-66D716E2-C319-4BF5-B937-BCB2D05E3921

P698

Q44807764-987DA315-806F-4AEF-84C5-17EAF788DD1D

P921

Q44807764-12998BC6-8867-459C-8911-9D609F478E9D

Q44807764-1980D240-AEDA-43E6-B6C7-8D00588B64D3

P356

P1433

Nature Immunology

P1476

Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway.

@en

P2093

Frank J Accurso

http://www.w3.org/2001/XMLSchema#string

Jasim Uddin

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Whitsett

http://www.w3.org/2001/XMLSchema#string

Kiwon W Park

http://www.w3.org/2001/XMLSchema#string

Leah M Flick

http://www.w3.org/2001/XMLSchema#string

Marsha Wills-Karp

http://www.w3.org/2001/XMLSchema#string

Raquel Keledjian

http://www.w3.org/2001/XMLSchema#string

Rong Yang

http://www.w3.org/2001/XMLSchema#string

Sowsan F Atabani

http://www.w3.org/2001/XMLSchema#string

Todd M Greer

http://www.w3.org/2001/XMLSchema#string

P304

388-392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NI1056

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Nicos A. Petasis

Yasmine Belkaid

Christopher L Karp

P577

2004-03-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15034576

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis